Pitavastatin Impurity 26

Development and validation of stability indicating UV spectrophotometric method for the determination of Pitavastatin calcium
By Aglawe, Konica Vijay; Kharat, Umesh Pralhad; Dongaonkar, Chaitali C.; Chavan, Vijayalaxmi A.
From World Journal of Pharmacy and Pharmaceutical Sciences (2016), 5(7), 1773-1787
 
Stability indicating HPTLC method for the estimation of pitavastatin calcium in presence of acid induced degradation product
By Damle, Mrinalini C.; Polawar, Anuradha R.
From International Journal of ChemTech Research (2014), 6(5), 2824-2833
 
Degradation pathway for pitavastatin calcium by validated stability indicating UPLC method
By Gomas, Antony Raj; Ram, Pannala Raghu; Srinivas, Nimmakayala; Sriramulu, Jadi
From American Journal of Analytical Chemistry (2010), 1(2), 83-90

Pitavastatin Impurity 26 is chemically 3-(Bromomethyl)-2-cyclopropyl-4-(4-fluorophenyl)quinoline. Pitavastatin Impurity 26 is supplied with detailed characterization data compliant with regulatory guideline. Pitavastatin Impurity 26 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Pitavastatin.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.